AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for NK-Cell Lymphoma

A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma NCT07044050Phase 11 site๐Ÿ“ Montpellier Emercell SAS ยท Tests: allogenic natural killer cells The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies NCT04329728Phase 1, Phase 211 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles AVM Biotechnology Inc ยท Tests: AVM0703 A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy NCT07628738Phase 21 site๐Ÿ“ Shanghai Ruijin Hospital ยท Tests: reduced-intensity radiotherapy Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome NCT06967038Phase 1, Phase 21 site๐Ÿ“ Shanghai Bangdong Gong ยท Tests: CAR-NK cell Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma NCT04803201Phase 296 sites๐Ÿ“ Little Rock๐Ÿ“ Duarte๐Ÿ“ La Jolla Alliance for Clinical Trials in Oncology ยท Tests: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies NCT07444632Phase 11 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Fludarabine, TGFBR2 KO CAR27/IL-15 NK cells, Cyclophosphamide JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06716658Phase 22 sites๐Ÿ“ Tianjin๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: JAK1 Inhibitor Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE NCT01555892Phase 13 sites๐Ÿ“ Houston๐Ÿ“ Houston๐Ÿ“ Houston Baylor College of Medicine ยท Tests: EBV-specific T cells: A, EBV-specific T cells: B Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma NCT06314334Phase 27 sites๐Ÿ“ Fuzhou๐Ÿ“ Nantong๐Ÿ“ Shanghai Fudan University ยท Tests: Sintilimab+Pegaspargase, P-GemOx, GELAD, IMRT Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL NCT06707259Phase 11 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: anti-CD19 IL10/IL15 CAR-NK Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768Phase 1, Phase 21 site๐Ÿ“ Shanghai Rong Tao ยท Tests: Tislelizumab, Zeprumetostat Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases NCT07727083n/a1 site๐Ÿ“ Shanghai Rong Tao Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma NCT07164560Phase 11 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Anti-TRBC1 CAR-T cells Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) NCT07225439Phase 12 sites๐Ÿ“ Cleveland๐Ÿ“ Cleveland Paolo Caimi, MD ยท Tests: Allogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, Fludarabine/cyclophosphamide Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma NCT05842707Phase 1, Phase 21 site๐Ÿ“ Shanghai Aibin Liang๏ผŒMD๏ผŒPh.D. ยท Tests: dualCAR-NK19/70 cell CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia NCT06696846Phase 11 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: CD70 CAR-NK A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) NCT07465835Phase 16 sites๐Ÿ“ New Haven๐Ÿ“ Atlanta๐Ÿ“ Grand Rapids Electra Therapeutics Inc. ยท Tests: ELA026 Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma NCT03719105EARLY Phase 16 sites๐Ÿ“ Birmingham๐Ÿ“ Orange๐Ÿ“ San Francisco New York Medical College ยท Tests: Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma NCT07000617Phase 23 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Beijing Peking University Cancer Hospital & Institute ยท Tests: DAPT regimen plus radiotherapy A Study of Ruxolitinib and Duvelisib in People With Lymphoma NCT05010005Phase 19 sites๐Ÿ“ Miami๐Ÿ“ Boston๐Ÿ“ Basking Ridge Memorial Sloan Kettering Cancer Center ยท Tests: Ruxolitinib, Duvelisib Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances NCT05092451Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies NCT06909474Phase 11 site๐Ÿ“ Wuhan Chongqing Precision Biotech Co., Ltd ยท Tests: Anti-CD5 CAR NK cells Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma NCT06376721Phase 1, Phase 21 site๐Ÿ“ Beijing Beijing Tongren Hospital ยท Tests: Linperlisib, Camrelizumab, Pegaspargase, Dexamethasone Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas NCT02859402Phase 22 sites๐Ÿ“ Busan๐Ÿ“ Daegu Keimyung University Dongsan Medical Center ยท Tests: Busulfan, Fludarabine PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06530550Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: PI3K inhibitor Novel Therapeutic Approach for Human T-cell Malignancies NCT06600568n/a2 sites๐Ÿ“ Naples๐Ÿ“ Padova Istituto Oncologico Veneto IRCCS ยท Tests: Translation analysis Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL NCT05472558Phase 11 site๐Ÿ“ Hanzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: anti-CD19 CAR-NK Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma NCT07283679Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: ONC-PluReceptor NK cells RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies NCT06732492Phase 11 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: RD13-02 cell infusion
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy